{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:13Z","timestamp":1791295633370,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>An over-expression of CD19 has been shown in B cells of systemic sclerosis (SSc) and B cells are thought to contribute to the induction of skin fibrosis in the tight skin mouse model. The aim was to define the outcome on safety and the change in skin score after rituximab therapy in SSc patients and to correlate the clinical characteristics with the levels of interleukin (IL)-6 and with the immune cell infiltrate detected by immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nine patients with SSc with mean age 40.9 \u00b1 11.1 years were treated with anti-CD20, 1 g at time 0 and after 14 days. Skin biopsy was performed at baseline and during the follow-up. B-cell activating factor (BAFF) and IL-6 levels were also determined at the follow-up times.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6 months patients presented a median decrease of the skin score of 43.3% (range 21.1-64.0%), and a decrease in disease activity index and disease severity index. IL-6 levels decreased permanently during the follow up. After treatment, a complete depletion of peripheral blood B cells was observed in all but 2 patients. Only 3 patients presented CD20 positive cells in the biopsy of the involved skin at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-CD20 treatment has been well tolerated and SSc patients experienced an improvement of the skin score and of clinical symptoms. The clear fall in IL-6 levels could contribute to the skin fibrosis improvement, while the presence of B cells in the skin seems to be irrelevant with respect to the outcome after B cell depletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN77554566.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar2965","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T15:14:54Z","timestamp":1269530094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":177,"title":["B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Silvia","family":"Bosello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tolusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigliola","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,25]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0889-857X(05)70297-0","volume":"22","author":"Y Okano","year":"1996","unstructured":"Okano Y: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1996, 22: 709-735. 10.1016\/S0889-857X(05)70297-0.","journal-title":"Rheum Dis Clin North Am"},{"key":"2800_CR2","first-page":"59","volume":"29","author":"G Famularo","year":"1989","unstructured":"Famularo G, Giacomelli R, Alesse E, Cifone MG, Morrone S, Boirivant M, Danese C, Perego MA, Santoni A, Tonietti G: Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol. 1989, 29: 59-63.","journal-title":"J Clin Lab Immunol"},{"key":"2800_CR3","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004, 50: 1918-1927. 10.1002\/art.20274.","journal-title":"Arthritis Rheum"},{"key":"2800_CR4","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","volume":"165","author":"S Sato","year":"2000","unstructured":"Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000, 165: 6635-6643.","journal-title":"J Immunol"},{"key":"2800_CR5","doi-asserted-by":"publisher","first-page":"12319","DOI":"10.1073\/pnas.1635114100","volume":"100","author":"ML Whitfield","year":"2003","unstructured":"Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003, 100: 12319-12324. 10.1073\/pnas.1635114100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","volume":"165","author":"N Asano","year":"2004","unstructured":"Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S: B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004, 165: 641-650.","journal-title":"Am J Pathol"},{"key":"2800_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI0215078","volume":"109","author":"E Saito","year":"2002","unstructured":"Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002, 109: 1453-1462.","journal-title":"J Clin Invest"},{"key":"2800_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","volume":"169","author":"M Hasegawa","year":"2006","unstructured":"Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353\/ajpath.2006.060205.","journal-title":"Am J Pathol"},{"key":"2800_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","volume":"172","author":"A Yoshizaki","year":"2008","unstructured":"Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008, 172: 1650-1663. 10.2353\/ajpath.2008.071049.","journal-title":"Am J Pathol"},{"key":"2800_CR10","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1172\/JCI24798","volume":"115","author":"I Novobrantseva","year":"2005","unstructured":"Novobrantseva I, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A: Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005, 115: 3072-3082. 10.1172\/JCI24798.","journal-title":"J Clin Invest"},{"key":"2800_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","volume":"138","author":"E Scala","year":"2004","unstructured":"Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pit\u00e0 O, Puddu P, Paganelli R, Russo G: Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004, 138: 540-546. 10.1111\/j.1365-2249.2004.02642.x.","journal-title":"Clin Exp Immunol"},{"key":"2800_CR12","first-page":"308","volume":"25","author":"M Hasegawa","year":"1998","unstructured":"Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of Interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998, 25: 308-316.","journal-title":"J Rheumatol"},{"key":"2800_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1465-9921-6-96","volume":"6","author":"M De Santis","year":"2005","unstructured":"De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistelli R, Danza FM, Zoli A, Ferraccioli F: Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005, 6: 96-106. 10.1186\/1465-9921-6-96.","journal-title":"Respir Res"},{"key":"2800_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000163802","volume":"61","author":"AE Koch","year":"1993","unstructured":"Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology. 1993, 61: 239-246. 10.1159\/000163802.","journal-title":"Pathobiology"},{"key":"2800_CR15","first-page":"296","volume":"25","author":"T Kadono","year":"1998","unstructured":"Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol. 1998, 25: 296-301.","journal-title":"J Rheumatol"},{"key":"2800_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1006\/cyto.2000.0822","volume":"13","author":"K Kondo","year":"2001","unstructured":"Kondo K, Okada T, Matsui T, Kato S, Date K, Yoshihara M, Nagata Y, Takagi H, Yoneda M, Sugie I: Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine. 2001, 13: 220-226. 10.1006\/cyto.2000.0822.","journal-title":"Cytokine"},{"key":"2800_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006, 54: 192-201. 10.1002\/art.21526.","journal-title":"Arthritis Rheum"},{"key":"2800_CR18","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/sj.jid.5700919","volume":"127","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol. 2007, 127: 2772-2780.","journal-title":"J Invest Dermatol"},{"key":"2800_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136\/ard.2008.095463.","journal-title":"Ann Rheum Dis"},{"key":"2800_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW: B cell depletion with Rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002\/art.24249.","journal-title":"Arthritis Rheum"},{"key":"2800_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","volume":"47","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S: Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology. 2008, 47: 552-553. 10.1093\/rheumatology\/kem357.","journal-title":"Rheumatology"},{"key":"2800_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10067-003-0733-2","volume":"22","author":"M Calguneri","year":"2003","unstructured":"Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I: The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol. 2003, 22: 289-294. 10.1007\/s10067-003-0733-2.","journal-title":"Clin Rheumatol"},{"key":"2800_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002\/art.1780230510.","journal-title":"Arthritis Rheum"},{"key":"2800_CR24","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol. 1988, 15: 202-205.","journal-title":"J Rheumatol"},{"key":"2800_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/ard.62.9.904","volume":"62","author":"G Valentini","year":"2003","unstructured":"Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV: Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003, 62: 904-905. 10.1136\/ard.62.9.904.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 29","key":"2800_CR26","first-page":"S39","volume":"21","author":"G Valentini","year":"2003","unstructured":"Valentini G, Silman AJ, Veale D: Assessment of disease activity. Clin Exp Rheumatol. 2003, 21 (Suppl 29): S39-S41.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 29","key":"2800_CR27","first-page":"S42","volume":"21","author":"TA Medsger Jr","year":"2003","unstructured":"Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W: Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003, 21 (Suppl 29): S42-S46.","journal-title":"Clin Exp Rheumatol"},{"key":"2800_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thx.2004.035436","volume":"60","author":"JJ Egan","year":"2005","unstructured":"Egan JJ, Martinez FJ, Wells AU, Williams T: Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005, 60: 270-273. 10.1136\/thx.2004.035436.","journal-title":"Thorax"},{"key":"2800_CR29","doi-asserted-by":"publisher","first-page":"v65","DOI":"10.1093\/rheumatology\/ken313","volume":"47 Suppl 5","author":"J Behr","year":"2008","unstructured":"Behr J, Furst DE: Pulmonary function tests. Rheumatol. 2008, 47 Suppl 5: v65-v67. 10.1093\/rheumatology\/ken313.","journal-title":"Rheumatol"},{"key":"2800_CR30","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1002\/art.22186","volume":"54","author":"EY Kissin","year":"2006","unstructured":"Kissin EY, Merkel PA, Lafyatis R: Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 2006, 54: 3655-3660. 10.1002\/art.22186.","journal-title":"Arthritis Rheum"},{"key":"2800_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1523-1747.ep12483971","volume":"97","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991, 97: 686-692. 10.1111\/1523-1747.ep12483971.","journal-title":"J Invest Dermatol"},{"key":"2800_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1365-2249.1994.tb07031.x","volume":"95","author":"I Choi","year":"1994","unstructured":"Choi I, Kang HS, Yang Y, Pyun KH: IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clin Exp Immunol. 1994, 95: 530-535.","journal-title":"Clin Exp Immunol"},{"key":"2800_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1165\/rcmb.2002-0262OC","volume":"29","author":"YP Moodley","year":"2003","unstructured":"Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA: Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol. 2003, 29: 490-498. 10.1165\/rcmb.2002-0262OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2800_CR34","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/art.22603","volume":"56","author":"JO Pers","year":"2007","unstructured":"Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P: BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren syndrome. Arthritis Rheum. 2007, 56: 1464-1477. 10.1002\/art.22603.","journal-title":"Arthritis Rheum"},{"key":"2800_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2006.060772","volume":"66","author":"F Lavie","year":"2007","unstructured":"Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X: Increase of B cell-activating factor of the TNF family (BAFF) after Rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007, 66: 700-703. 10.1136\/ard.2006.060772.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar2965\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:55:50Z","timestamp":1728370550000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar2965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,25]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,4]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1186\/ar2965","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,25]]},"assertion":[{"value":"5 May 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R54"}}